US 3845770A
· Theeuwes et al.
· 1974
[cited by applicant]
US 4112095A
· Allen, Jr. et al.
· 1978
[cited by applicant]
US 4230705A
· Allen, Jr. et al.
· 1980
[cited by applicant]
US 4242515A
· Trust et al.
· 1980
[cited by applicant]
US 4326525A
· Swanson et al.
· 1982
[cited by applicant]
US 4902514A
· Barclay et al.
· 1990
[cited by applicant]
US 4992445A
· Lawter et al.
· 1991
[cited by applicant]
US 5001139A
· Lawter et al.
· 1991
[cited by applicant]
US 5023252A
· Hsieh et al.
· 1991
[cited by applicant]
US 5616345A
· Geoghegan et al.
· 1997
[cited by applicant]
US 5905079A
· Sargent et al.
· 1999
[cited by applicant]
US 6589952B2
· Bakthavatchalam et al.
· 2003
[cited by applicant]
US 7863279B2
· Even et al.
· 2011
[cited by applicant]
US 8030305B2
· Lu et al.
· 2011
[cited by applicant]
US 8173654B2
· Lu et al.
· 2012
[cited by applicant]
US 8198448B2
· Albrecht et al.
· 2012
[cited by applicant]
US 8212041B2
· Albrecht et al.
· 2012
[cited by applicant]
US 8217177B2
· Albrecht et al.
· 2012
[cited by applicant]
US 8524900B2
· Albrecht et al.
· 2013
[cited by applicant]
US 8937060B2
· Cid-Nunez et al.
· 2015
[cited by applicant]
US 8952034B2
· Corkey et al.
· 2015
[cited by applicant]
US 9066954B2
· Albrecht et al.
· 2015
[cited by applicant]
US 9371329B2
· Corkey et al.
· 2016
[cited by applicant]
US 20020049208A1
· Bakthavatchalam et al.
· 2002
[cited by applicant]
US 20080200536A1
· Moon et al.
· 2008
[cited by applicant]
US 20090203707A1
· Rajamani et al.
· 2009
[cited by applicant]
US 20100088778A1
· Mulley et al.
· 2010
[cited by applicant]
US 20130315895A1
· Farrell et al.
· 2013
[cited by applicant]
US 20150344457A1
· Duncan et al.
· 2015
[cited by applicant]
US 20210188839A1
· Reddy et al.
· 2021
[cited by applicant]
US 20230322790A1
· Reddy et al.
· 2023
[cited by applicant]
CA 1080712A
· 1980
[cited by applicant]
CN 102725290A
· 2012
[cited by applicant]
EA 201290121A1
· 2012
[cited by applicant]
EA 201991306A1
· 2020
[cited by applicant]
EP 2818471A1
· 2014
[cited by applicant]
JP S5340798A
· 1978
[cited by applicant]
JP 11503437A
· 1999
[cited by applicant]
JP 2017001991A1
· 2017
[cited by applicant]
JP 7495962B2
· 2024
[cited by applicant]
TW 201116528A
· 2011
[cited by applicant]
WO 2006061428A2
· 2006
[cited by applicant]
WO 2007075567A1
· 2007
[cited by applicant]
WO 2008008539A2
· 2008
[cited by applicant]
WO 2010053757A1
· 2010
[cited by applicant]
WO 2010056865A1
· 2010
[cited by applicant]
WO 2010074807A1
· 2010
[cited by applicant]
WO 2011014462A1
· 2011
[cited by applicant]
WO 2011056985A2
· 2011
[cited by applicant]
WO 2012003392A1
· 2012
[cited by applicant]
WO 2012065546A1
· 2012
[cited by applicant]
WO 2012154760A1
· 2012
[cited by applicant]
WO 2013006463A1
· 2013
[cited by applicant]
WO 2013043925A1
· 2013
[cited by applicant]
WO 2014179492A1
· 2014
[cited by applicant]
WO 2015095370A1
· 2015
[cited by applicant]
WO 2015158283A1
· 2015
[cited by applicant]
WO 2015194670A1
· 2015
[cited by applicant]
WO 2015197567A1
· 2015
[cited by applicant]
WO 2018067786A1
· 2018
[cited by applicant]
WO 2018098491A1
· 2018
[cited by applicant]
WO 2018098499A1
· 2018
[cited by applicant]
WO 2018098500A1
· 2018
[cited by applicant]
WO 2018148745A1
· 2018
[cited by applicant]
WO 2018187480A1
· 2018
[cited by applicant]
WO 2019035951A1
· 2019
[cited by applicant]
WO 2019232209A1
· 2019
[cited by applicant]
WO 2020069322A1
· 2020
[cited by applicant]
WO 2021108513A1
· 2021
[cited by applicant]
WO 2021108625A1
· 2021
[cited by applicant]
US 8,754,103 B2, 06/2014, Corkey et al. (withdrawn)
[cited by applicant]
Young, Lee (Authorized Officer), International Search Report and Written Opinion issued Apr. 6, 2021 in corresponding International Application No. PCT/US2020/062317, 14 pages.
[cited by applicant]
Flynn et al. “Correlation and Prediction of Mass Transport across Membranes I: Influence of Alkyl Chain Length on Flux-Determining Properties of Barrier and Diffusant”, Journal of Pharmaceutical Sciences. 1972. vol. 61(…
[cited by applicant]
Kahlig et al., The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers. Epilepsia. Mar. 2022;63(3):69…
[cited by applicant]
Kolobov et al., Development of a method for the synthesis of compounds of the series 5-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)benzene-1,3-diamine. Khimicheskaya Tekhnologiya. Jan. 2010;11(9):522-524.
[cited by applicant]
Wang et al., Multiple Nav1.5 isoforms are functionally expressed in the brain and present distinct expression patterns compared with cardiac Nav1.5. Mol Med Rep. Jul. 2017;16(1):719-729.
[cited by applicant]
Chinese Office Action for Application No. 201980047216.4, dated Sep. 24, 2024, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/019652, dated Sep. 21, 2023, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/019659, dated Sep. 28, 2023, 10 pages.
[cited by applicant]
U.S. Appl. No. 16/464,468, filed May 28, 2019, U.S. Pat. No. 1,629,146.
[cited by applicant]
U.S. Appl. No. 18/119,963, filed Mar. 10, 2023, 2023-0322790.
[cited by applicant]
U.S. Appl. No. 17/058,187, filed Nov. 24, 2020, U.S. Pat. No. 11,866,439.
[cited by applicant]
U.S. Appl. No. 17/280,485, filed Mar. 26, 2021, 2021-0403476.
[cited by applicant]
U.S. Appl. No. 17/102,586, filed Nov. 24, 2020, U.S. Pat. No. 11,014,931.
[cited by applicant]
U.S. Appl. No. 17/214,343, filed Mar. 26, 2021, U.S. Pat. No. 11,731,976.
[cited by applicant]
U.S. Appl. No. 17/025,018, filed Mar. 23, 2022, U.S. Pat. No. 11,731,978.
[cited by applicant]
U.S. Appl. No. 18/236,156, filed Aug. 21, 2023, 2024-0132501.
[cited by applicant]
U.S. Appl. No. 18/860,376, filed Oct. 25, 2024.
[cited by applicant]
U.S. Appl. No. 18/927,451, filed Oct. 25, 2024.
[cited by applicant]
U.S. Appl. No. 18/860,406, filed Oct. 25, 2024.
[cited by applicant]
De Lera Ruiz et al., Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. J Med Chem. Sep. 24, 2015;58(18):7093-118.
[cited by applicant]
European Office Action for Application No. 19810530.6, dated Jan. 31, 2022, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2017/063533, dated Jun. 6, 2019, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/034653, dated Dec. 10, 2020, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/053467, dated Apr. 8, 2021, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2020/062179, dated Jun. 9, 2022, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/Us2020/062317, dated Jun. 9, 2022, 12 pages.
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2017/063533 mailed Mar. 29, 2019 (10 pages).
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2017/063534 mailed Mar. 28, 2019 (11 pages).
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2018/00224 mailed Nov. 5, 2018 (8 pages).
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2018/018044 mailed May 24, 2018 (10 pages).
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2018/026099 mailed Aug. 10, 2018 (9 pages).
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2019/053467 mailed Jan. 14, 2020 (9 pages).
[cited by applicant]
Zablocki et al. “Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late INai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties,” Journal of Medicinal…
[cited by applicant]
Zaza et al., (2008). “Pathophysiology and pharmacology of the cardiac ‘late sodium current’,” Pharmacology & Therapeutics, 119(3):326-339.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/638,725 mailed on Apr. 2, 2021, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2018/018044 filed on Feb. 13, 2018, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2018/026099 filed on Apr. 4, 2018, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2017/063507 filed on Nov. 28, 2017, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2017/063534 filed on Nov. 28, 2017, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2018/000224 filed on Aug. 15, 2018, 6 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Feb. 25, 2021, for PCT Application No. PCT/US2020/062179 filed on Nov. 25, 2020, 7 pages.
[cited by applicant]
International Search Report and Written Opinion received for International Patent Application No. PCT/US2020/062317 mailed on Apr. 6, 2021, 14 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/638,725 mailed on Dec. 11, 2020, 16 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/887,906 mailed on Jun. 10, 2021, 18 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/464,483 mailed on Jun. 30, 2021, 22 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/485,581 mailed on Mar. 10, 2021, 8 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 17/102,586 mailed on Jan. 26, 2021, 14 pages.
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2019/034653 mailed Aug. 9, 2019 (9 pages).
[cited by applicant]
File Registry On STN, RN 1347643-11-1, Entered STN: Dec. 2, 2011.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/500,795 mailed on Apr. 13, 2022, 18 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/885,605 mailed on Jan. 28, 2022, 10 pages.
[cited by applicant]
Restriction Requirement received for U.S. Appl. No. 16/500,795 mailed on Dec. 16, 2021, 12 pages.
[cited by applicant]
European Communication to Rule 62 EPC issued in European Patent Application No. 19810530.6 dated Jan. 31, 2022 (9 pages).
[cited by applicant]
European Communication to Rules 70(2) and 70a(2) EPC issued in European Patent Application No. 19810530.6 dated Feb. 17, 2022 (1 page).
[cited by applicant]
Thakur (Controller), Indian First Examination Report issued in Indian Patent Application No. 202017056206 dated Jun. 14, 2022, with English language translation (7 pages).
[cited by applicant]
Chinese Office Action issued in Chinese Patent Application No. 201780084790.8 dated Mar. 9, 2022, with English language translation (23 pages).
[cited by applicant]
Japanese Notice of Reasons for Refusal issued in Japanese Patent Application No. 2019-548536 dated Oct. 21, 2021, with English language translation (8 pages).
[cited by applicant]
Eurasian Office Action issued in Eurasian Patent Application No. 201991306 dated Aug. 24, 2021, with English language translation (6 pages).
[cited by applicant]
Eurasian Office Action issued in Eurasian Patent Application No. 201991306 dated Feb. 25, 2021, with English language translation (8 pages).
[cited by applicant]
Eurasian Office Action issued in Eurasian Patent Application No. 202092908 dated Feb. 21, 2022, with English language translation (7 pages).
[cited by applicant]
Wei, Chen (Authorized Officer), Singapore Search Report and Written Opinion issued in Singapore Patent Application No. 11202011879R dated May 6, 2022, (10 pages).
[cited by applicant]
Koltun, D. O. et al., “Discovery of triazolopyridinone GS 462808, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine”. Bioorganic & Medic…
[cited by applicant]
Albright et al. “Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines,” J. Med. Chem. (1981) vol. 24, pp. 592-600.
[cited by applicant]
Anderson et al. “Unexpected efficacy of a novel sodium channel modulator in Dravet Syndrome,” Scientific Reports. 2017.
[cited by applicant]
Anderson et al., “Antiepileptic activity of preferential inhibitors of persistent sodium current,” Epilepsia (2014), 55(8), 1274-1283.
[cited by applicant]
Baker et al. “The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy,” Epilepsia, 2018, 1166-1176.
[cited by applicant]
Barbieri et al. “Lale sodium current blocker GS967 inhibits persistent currents induced by familial hemiplegic migraine type 3 mutations of the SCN1 A gene,” The Journal of Headache and Pain (2019) vol. 20, No. 107, pp.…
[cited by applicant]
Belardinelli et al. “A Novel, Potent, and Selective Inhibitor of Cardiac Late Sodium Current Suppresses Experimental Arrhythmias,” J. Pharmacol. Exp. Ther. (2013) vol. 344, pp. 23-32.
[cited by applicant]
Berge et al., (1977). Pharmaceutical salts, J. Pharmaceutical Sciences, 66(1):1-19.
[cited by applicant]
Burbano et al., (2018). “Characterization of a Novel Knock-in Mouse Model of KCNT1 Epileptic Encephalopathy (P2.273),” Neurology, 90(15 Supplement), 2 pages. Abstract Only.
[cited by applicant]
Cannon, J. G., (1995). “Chapter Nineteen: Analog Design,” Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience, pp. 783-802.
[cited by applicant]
Chaplan et al., (1994). “Quantitative assessment of tactile allodynia in the rat paw,” J Neurosci Meth., 53:55-63.
[cited by applicant]
Dorwald, F. Z., (2005). “Side Reactions in Organic Synthesis,” Wiley: VCH, Weinheim, 37 pages.
[cited by applicant]
Fukaya et al., (2013). “Identification of a Novel Benzoxazolone Derivative as a Selective, Orally Active 18 kDa Translocator Protein (TSPO) Ligand,” J. of Med. Chem., 56(20): 8191-8195.
[cited by applicant]
Guan et al. “Synthesis and anticonvulsant activity of a new 6-alkoxy-[1,2,4]-triazolo[4,3-b]pyridazine,” Eur. J. Med. Chem. (2010) vol. 45, pp. 1746-1752.
[cited by applicant]
Hackam et al., (2006). “Translation of research evidence from animals to humans,” JAMA, 296(14):1731-1732.
[cited by applicant]
Jordan et al., (2003). “Tamoxifen: a most unlikely pioneering medicine,” Nat Rev Drug Discov., 2(3):205-213.
[cited by applicant]
Kearney et al., (2001 ). “A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities,” Neuroscience, 702(2):307-317. Abstract Only.
[cited by applicant]
Kim et al., (1992). “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,” Pain, 50:355-363.
[cited by applicant]
Li et al., (2018). “Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsies,” American Epilepsy Society, 28 pages.
[cited by applicant]
Patel et al., (2019). “Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: A back-translational study of oxcarbazepine,” Eur J Pain, 23:183-197.
[cited by applicant]
Petrou et al., (2018). “Abstract: Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsies,” American Epilepsy Society, available online at <https://www.aesnet.org/abstractslisting/antisense-oligonucleoti…
[cited by applicant]
PUBCHEM-CID 58763997 Create Date: Aug. 19, 2012 (14 pages).
[cited by applicant]
PUBCHEM-CID 597467 Create Date: Mar. 27, 2005 (15 pages).
[cited by applicant]
PUBCHEM-CID 82381512 Create Date: Oct. 20, 2014 (10 pages).
[cited by applicant]
PUBCHEM-CID 89077556 Create Date: Feb. 13, 2015 (11 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Apr. 14, 2019 (36 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Apr. 2018 (55 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Apr. 23, 2019 (45 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Feb. 2018 (29 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Jan. 15, 2020 (22 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Jan. 2018 (23 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Mar. 20, 2018 (264 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Mar. 20, 2018 (83 pages).
[cited by applicant]
BTN Chemical Structure Search Results dated Mar. 6, 2017 (480 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Mar. 6, 2017 (511 pages).
[cited by applicant]
STN Chemical Structure Search Results dated May 18, 2016 (102 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Nov. 1, 2017 (107 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Nov. 21, 2017 (85 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Nov. 3, 2017 (57 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Nov. 6, 2017 (123 pages).
[cited by applicant]
STN Chemical Structure Search Results dated Nov. 6, 2017 (7 pages).
[cited by applicant]
Venkatesh et al., (2000). “Role of the development scientist in compound lead selection and optimization,” J Pharm Sci., 89(2):145-54.
[cited by applicant]
Wagnon et al., (2015). “Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy,” Human Molecular Genetics, 24(2):506-515.
[cited by applicant]
Wilen et al., (1977). “Strategies in optical resolutions,” Tetrahedron, 33(21 ):2725-2736.
[cited by applicant]
Woodland et al., (2015). “Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library,” ChemMedChem, 10(11 ): 1809-1820.
[cited by applicant]
Wengert et al. “Prax330 reduces persistent and resurgent sodium channel currents and neuronal hyperexcitability of subiculum neurons in a mouse model of SCN8A epileptic encephalopathy,” Neuropharmacology (2019) vol. 158…
[cited by applicant]
Written Opinion of the International Searching Authority and International Search Report for PCT/US2017/063507 mailed Mar. 29, 2019 (9 pages).
[cited by applicant]